EZH2 alterations in follicular lymphoma: biological and clinical correlationsBlood Cancer Journal - Tập 7 Số 4 - Trang e555-e555
Sarah Huet, Luc Xerri, Bruno Tesson, Sylvain Mareschal, Sébastien Taix, Lénaïg Mescam-Mancini, Emilie Sohier, Marjorie Carrère, Julien Lazarovici, Olivier Casasnovas, Laurie Tonon, Sandrine Boyault, Sandrine Hayette, Corinne Haïoun, Bettina Fabiani, Alain Viari, Fabrice Jardin, Gilles Salles
AbstractThe histone methyltransferase EZH2 has an essential role in the development of follicular lymphoma (FL). Recurrent gain-of-function mutations inEZH2have been described in 25% of FL patients and induce aberrant methylation of histone H3 lysine 27 (H3K27). We evaluated the role ofEZH2genomic gains in FL bi...... hiện toàn bộ
IL-10 induces the development of immunosuppressive CD14+HLA-DRlow/− monocytes in B-cell non-Hodgkin lymphomaBlood Cancer Journal - Tập 5 Số 7 - Trang e328-e328
B Xiu, Yi Lin, D M Grote, Steven C. Ziesmer, Michael P. Gustafson, Meridean Maas, Z. Zhang, Allan B. Dietz, Luis F. Porrata, Anne J. Novak, A-B Liang, Z-Z Yang, S. Ansell
AbstractThe biological role of monocytes and macrophages in B-cell non-Hodgkin lymphoma (NHL) is not fully understood. We have previously reported that monocytes from patients with B-cell NHL have an immunosuppressive CD14+HLA-DRlow/− phenotype that correlates with a poor prognosis. However, the underlying mechanism by whic...... hiện toàn bộ
NPM-ALK mediates phosphorylation of MSH2 at tyrosine 238, creating a functional deficiency in MSH2 and the loss of mismatch repairBlood Cancer Journal - Tập 5 Số 5 - Trang e311-e311
Kathleen M. Bone, P Wang, Fang Wu, Chenming Wu, L Li, Julinor Bacani, Susan E. Andrew, Rai‐Hua Lai
AbstractThe vast majority of anaplastic lymphoma kinase-positive anaplastic large cell lymphoma (ALK+ALCL) tumors express the characteristic oncogenic fusion protein NPM-ALK, which mediates tumorigenesis by exerting its constitutive tyrosine kinase activity on various substrates. We recently identified MSH2, a protein central to DNA mismatch repair (MMR), as a nove...... hiện toàn bộ
Myelofibrosis Treatment Algorithm 2018Blood Cancer Journal - Tập 8 Số 8
Ayalew Tefferi, Paola Guglielmelli, Animesh Pardanani, Alessandro M. Vannucchi
AbstractTwo novel prognostic systems for primary myelofibrosis (PMF) were recently unveiled: GIPSS (genetically inspired prognostic scoring system) and MIPSS70 (mutation-enhanced international prognostic scoring system for transplant-age patients). GIPSS is based exclusively on genetic markers: mutations and karyotype. MIPSS70 includes mutations and clinical risk f...... hiện toàn bộ
Staphylococcus aureus enterotoxins induce FOXP3 in neoplastic T cells in Sézary syndromeBlood Cancer Journal - Tập 10 Số 5
Andreas Willerslev-Olsen, Terkild B. Buus, Claudia Nastasi, Edda Blümel, Maria Gluud, Charlotte M. Bonefeld, Carsten Geisler, Lise M. Lindahl, Maarten H. Vermeer, Mariusz A. Wasik, Lars Iversen, Jürgen C. Becker, Mads Hald Andersen, Lise Mette Rahbek Gjerdrum, Ivan V. Litvinov, Thomas Litman, Thorbjørn Krejsgaard, Anders Woetmann, Niels Ødum
AbstractSézary syndrome (SS) is a heterogeneous leukemic subtype of cutaneous T-cell lymphoma (CTCL) with generalized erythroderma, lymphadenopathy, and a poor prognosis. Advanced disease is invariably associated with severe immune dysregulation and the majority of patients die from infectious complications caused by microorganisms such as,Staphylococc...... hiện toàn bộ
Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cellsBlood Cancer Journal - Tập 3 Số 6 - Trang e120-e120
David Chiron, Sophie Maïga, Sylvanie Surget, Géraldine Descamps, Patricia Gomez‐Bougie, Sory Traoré, Nelly Robillard, Philippe Moreau, Steven Le Gouill, R Bataille, Martine Amiot, Catherine Pellat‐Deceunynck
CAR-T cell therapy: current limitations and potential strategiesBlood Cancer Journal - Tập 11 Số 4
Robert C. Sterner, Rosalie M. Sterner
AbstractChimeric antigen receptor (CAR)-T cell therapy is a revolutionary new pillar in cancer treatment. Although treatment with CAR-T cells has produced remarkable clinical responses with certain subsets of B cell leukemia or lymphoma, many challenges limit the therapeutic efficacy of CAR-T cells in solid tumors and hematological malignancies. Barriers to effecti...... hiện toàn bộ